Physician profile
Scott D Hansen
NPI 1992832935
$3,293.69
in general payments reported to CMS, 2019-2025
13 companies · $730 in 2025
The $730 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $164 · 2021: $529 · 2022: $322 · 2023: $506 · 2024: $612 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,191.31 | 2019-2025 | Precision 1, Precision7, Total30 |
| Bausch & Lomb Americas INC. | $731.77 | 2022-2025 | Infuse, Alden Scleral Zenlens |
| Johnson & Johnson Vision Care, INC. | $276.57 | 2019-2025 | Acuvue |
| Coopervision INC. | $240.78 | 2020-2024 | Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $238.87 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $167.94 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $143.18 | 2024 | Tearcare System |
| Astellas Pharma US INC | $110.31 | 2024-2025 | Izervay |
| Biotissue Holdings INC. | $61.90 | 2025 | |
| Kala Pharmaceuticals, INC. | $46.98 | 2021 | |
| Lombart Brothers, INC. | $41.27 | 2023 | Opd-III |
| Abbvie INC. | $22.25 | 2023 | |
| Lkc Technologies, INC. | $20.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.